Calliditas Therapeutics AB

Published: 23.11.2017

Calliditas Therapeutics AB (formerly Pharmalink AB) announced today that the US Food & Drug Administration (FDA) has accepted its Phase 3 study design for its lead candidate Nefecon. A global Phase 3 program in IgA nephropathy has been initiated, and patient enrolment is expected to start in 2018.

Contact us